The control of biologics microbiological impurities, contaminants, and mimetics is evolving.
Kevin Williams
Advertisement
Articles by Kevin Williams
The recognition that microbial artifacts are capable of modulating the mammalian immune system is an emerging view of biologic drug contamination control testing.
Low endotoxin recovery represents an opportunity to add value to the characterization of biologic drug products.
Advertisement
Latest Updated Articles
Endotoxin Test Concerns of Biologics: The Role of Endotoxin as a Quality Indicator in Biologic Manufacturing ProcessesPublished: July 1st 2015 | Updated:
The Emerging View of Endotoxin as an IIRMIPublished: February 1st 2016 | Updated:
The Immune Context in Microbiological TestingPublished: September 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
